Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of “Hold” by Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has earned an average recommendation of “Hold” from the eight ratings firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $3.9417.

Several equities analysts recently issued reports on the stock. William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. Wall Street Zen cut Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 28th. Canaccord Genuity Group cut their price target on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Morgan Stanley reissued an “underperform” rating and issued a $3.50 price target on shares of Definitive Healthcare in a research report on Thursday, December 18th. Finally, Barclays decreased their price objective on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research note on Monday, December 8th.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Cash position strengthened — cash and cash equivalents rose to about $163.6M (up ~55% YoY), providing a larger liquidity buffer. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Positive Sentiment: Revenue roughly in line with expectations — Q4 revenue was about $61.5M, essentially flat YoY and slightly above some estimates, showing demand stability for the data/analytics business. Definitive Healthcare Q4 2025 Press Release / Slide Deck
• Neutral Sentiment: Company filed full Q4 release, slide deck and hosted a conference call — useful for details on customer trends and cost initiatives; review management commentary for color. Q4 Slide Deck / Conference Call
• Negative Sentiment: Guidance disappointed — Q1 EPS guided to $0.03 (vs. consensus ~$0.05) and FY‑2026 EPS guided to $0.14–0.17 (vs. consensus ~$0.21); revenue guidance of $220M–$226M also trails estimates, a main driver of the downward move. Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
• Negative Sentiment: Profitability metrics mixed/worse in some reports — one summary shows operating loss widening and a larger net loss / diluted EPS miss (Quiver reports diluted EPS -$0.09 and wider losses), which weighed on sentiment; note some sources reported a $0.06 EPS beat — check the company release and call transcript for reconciliation. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Negative Sentiment: Institutional selling visible — several large funds reduced or exited positions in Q4 (e.g., Palisade, Goldman, NY State Pension), which can amplify downward pressure near-term. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings

Definitive Healthcare Trading Down 0.7%

NASDAQ DH opened at $1.40 on Friday. Definitive Healthcare has a one year low of $1.36 and a one year high of $5.22. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. The company has a market capitalization of $197.90 million, a price-to-earnings ratio of -0.84 and a beta of 1.59. The company’s 50-day simple moving average is $2.21 and its two-hundred day simple moving average is $2.89.

Institutional Trading of Definitive Healthcare

Several hedge funds have recently modified their holdings of DH. Goldman Sachs Group Inc. grew its position in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after buying an additional 7,404,363 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Definitive Healthcare by 1.6% in the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock valued at $8,417,000 after acquiring an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Definitive Healthcare by 11.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after acquiring an additional 127,055 shares in the last quarter. Bank of America Corp DE grew its holdings in Definitive Healthcare by 23.7% in the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after purchasing an additional 147,599 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Definitive Healthcare by 0.4% during the second quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after purchasing an additional 3,066 shares in the last quarter. 98.67% of the stock is owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.